Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $445,067.84 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) CEO Christopher Gibson sold 48,272 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total transaction of $445,067.84. Following the sale, the chief executive officer now directly owns 774,703 shares of the company’s stock, valued at approximately $7,142,761.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Gibson also recently made the following trade(s):

  • On Wednesday, January 3rd, Christopher Gibson sold 30,853 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.49, for a total transaction of $292,794.97.
  • On Wednesday, December 6th, Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.49, for a total transaction of $448,119.21.

Recursion Pharmaceuticals Stock Up 1.9 %

RXRX opened at $10.09 on Monday. The company has a market cap of $2.19 billion, a price-to-earnings ratio of -6.91 and a beta of 0.63. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.54 and a 52-week high of $16.75. The firm’s fifty day simple moving average is $9.88 and its two-hundred day simple moving average is $8.61.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $10.53 million for the quarter, compared to analysts’ expectations of $12.20 million. Recursion Pharmaceuticals had a negative net margin of 617.74% and a negative return on equity of 64.20%. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.68 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on RXRX. TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. JPMorgan Chase & Co. dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, November 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, January 16th.

Check Out Our Latest Research Report on Recursion Pharmaceuticals

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RXRX. Swiss National Bank lifted its stake in shares of Recursion Pharmaceuticals by 7.6% in the first quarter. Swiss National Bank now owns 94,300 shares of the company’s stock worth $675,000 after buying an additional 6,700 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Recursion Pharmaceuticals by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock worth $2,676,000 after buying an additional 6,294 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 55.4% in the first quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock worth $458,000 after buying an additional 22,833 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Recursion Pharmaceuticals by 4.0% in the first quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock worth $887,000 after buying an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 8.1% in the first quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock worth $47,338,000 after buying an additional 497,504 shares in the last quarter. 57.82% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Articles

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.